Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$1.66B, compared with -$1.53B a year earlier.
Context
- Retained earnings amounted to 2765.4% of total assets at the end of Q1 FY2026, up 984.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -8.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (1.63B) USD
- Year-over-year change
- -8.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.63B) | -8.2% |
| FY2024 | 2024-12-31 | (1.5B) | -7.0% |
| FY2023 | 2023-12-31 | (1.41B) | -22.4% |
| FY2022 | 2022-12-31 | (1.15B) | -20.1% |
| FY2021 | 2021-12-31 | (956.27M) | — |
Retained Earnings vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -8.0% is the 2nd highest of 11, against a peer median of -16.7%.
- Retained earnings amounts to 2765.4% of total assets for SGMO, versus a peer median of 391.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$139.61M USD | -26.7% | — | 269.1% | |
| Mar 2026 | -$173.89M USD | -45.4% | — | 59.2% | |
| Mar 2026 | -CHF 323.66M CHF | -24.1% | — | 370.3% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | -$405.05M USD | -13.4% | — | 1001.9% |
| Dec 2025 | -€435.36M EUR | -12.7% | — | 694.4% | |
| Mar 2026 | -$456.67M USD | -17.6% | — | 235.7% | |
| Mar 2026 | -$615.48M USD | -5.5% | — | 475.8% | |
| Mar 2026 | -$616.88M USD | -84.5% | — | 883.8% | |
| Mar 2026 | -$763.82M USD | -15.7% | — | 232.3% | |
| Mar 2026 | -$995.88M USD | -8.5% | — | 412.0% | |
| Mar 2026 | -$1.66B USD | -8.0% | — | 2765.4% | |
| Peer median (excluding SGMO) | — | -16.7% | — | 391.1% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 178.87M | 100.44M | 45.2M | 41.92M | 20.95M |
| Short-term Investments | 197.68M | 177.19M | 35.8M | 0 | 0 |
| Net Receivables | 6.36M | 4.47M | 4.07M | 4.6M | 10.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 9.26M | 5.18M | 4.37M |
| Total Current Assets | 398.77M | 300.33M | 94.33M | 51.69M | 35.83M |
| Property, Plant & Equipment (Net) | 124.7M | 125.53M | 52.87M | 34.76M | 14.11M |
| Goodwill | 39.7M | 37.55M | 0 | 0 | 0 |
| Intangible Assets | 53.76M | 50.73M | 0 | 0 | 0 |
| Long-term Investments | 88.17M | 29.85M | 1.5M | 1.5M | 0 |
| Tax Assets | 0 | 6.27M | 0 | 0 | 0 |
| Other Non-current Assets | 16.82M | 12.25M | 16.63M | 13.69M | 9.81M |
| Total Non-current Assets | 323.15M | 262.18M | 70.99M | 49.94M | 23.92M |
| Total Assets | 721.92M | 562.51M | 165.32M | 101.64M | 59.75M |
| Account Payables | 9.76M | 22.42M | 15.26M | 15.49M | 14.44M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 4.07M | 10.14M |
| Deferred Revenue | 85.71M | 51.78M | 0 | 7.56M | 899K |
| Other Current Liabilities | 20.84M | 11.89M | 11.73M | 14.57M | 17.72M |
| Total Current Liabilities | 127.89M | 111.71M | 47.73M | 45.81M | 42.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 6.65M | 6.27M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 166.78M | 109.38M | 0 | 5.87M | 5.87M |
| Other Non-current Liabilities | 1.22M | 1.21M | 1.19M | 933K | 580K |
| Total Non-current Liabilities | 218.69M | 155.84M | 34.7M | 33.06M | 31.55M |
| Total Liabilities | 346.58M | 267.55M | 82.43M | 78.87M | 74.01M |
| Common Stock | 1.46M | 1.67M | 1.78M | 2.13M | 3.51M |
| Retained Earnings | (956.27M) | (1.15B) | (1.41B) | (1.5B) | (1.63B) |
| Accumulated OCI | (3.99M) | (8.4M) | (4.6M) | (7.53M) | (1.46M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 375.34M | 294.96M | 82.89M | 22.77M | (14.27M) |
| Total Debt | 48.08M | 43.11M | 38.1M | 30.57M | 26.8M |
| Net Debt | (130.79M) | (57.34M) | (7.1M) | (11.35M) | 5.85M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.